Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial
Authors:
- Elizabeth PrittsEPElizabeth Pritts
- Eric VittinghoffEVEric Vittinghoff
- Karen McClishKMKaren McClish
- Kevin S. MorganKMKevin S. Morgan
- Robert B. JaffeRJRobert B. Jaffe
- 1 January 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 105 (1) , 161-166
Abstract
To examine the efficacy of extended-release venlafaxine for the treatment of postmenopausal hot flushes. Eighty postmenopausal women with more than 14 hot flushes per week were randomized to receive treatment with extended-release venlafaxine or placebo. Participants received 37.5 mg daily for 1 week, followed by 75 mg daily for 11 weeks. Daily hot flush severity scores and adverse effects were recorded by subjects. Baseline and monthly follow-up questionnaires assessed patient-perceived hot flush score, quality of life, and sexual function. Participants were treated for 12 weeks. Of the 80 subjects who enrolled in the study, 40 were in the treatment group and 40 in the control group. Of these, 61 completed the study (treatment, n = 29; control, n = 32). Subjective assessment at monthly visits of the effects of hot flush symptoms on daily living were significantly improved in the treatment group (P < .001). Hot flush severity scores based on daily diaries were somewhat lower in the treatment group, but the between-group difference did not reach statistical significance (P = .25). Three side effects, dry mouth, sleeplessness, and decreased appetite, were significantly more frequent in the venlafaxine group, but others, including dizziness, tremors, anxiety, diarrhea, and rash, were significantly less frequent. Ninety-three percent of participants in the venlafaxine group chose to continue treatment at the conclusion of the study. Extended-release venlafaxine, 75 mg per day, is an effective treatment for postmenopausal hot flushes in otherwise healthy women, based on a significant decrease in patient-perceived hot flush score.Keywords
This publication has 15 references indexed in Scilit:
- Estrogen plus Progestin and the Risk of Coronary Heart DiseaseNew England Journal of Medicine, 2003
- Paroxetine Controlled Release in the Treatment of Menopausal Hot FlashesJAMA, 2003
- A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a centuryMenopause, 2002
- A Pilot Trial of Paroxetine for the Treatment of Hot Flashes and Associated Symptoms in Women with Breast CancerJournal of Pain and Symptom Management, 2002
- Phase III Evaluation of Fluoxetine for Treatment of Hot FlashesJournal of Clinical Oncology, 2002
- The role of serotonin in hot flushesMaturitas, 2000
- Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program StudyAnnals of Internal Medicine, 2000
- Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancerPsycho-Oncology, 1998
- Megestrol Acetate for the Prevention of Hot FlashesNew England Journal of Medicine, 1994
- Menopausal Age and Symptomatology in a General PracticeJournal of Biosocial Science, 1973